Table III.
Disease-free survival (DFS) and overall survival (OS) by clinicopathological characteristics and VEGF expression level.
| DFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | Cases (n=90) | Events (n=20) | 5-year survival (%) | P-value | Cases (n=96) | Events (n=9) | 5-year survival (%) | P-value |
| Age, years | 0.679 | 0.719 | ||||||
| <50 | 45 | 9 | 80.0 | 47 | 4 | 91.5 | ||
| ≥50 | 45 | 11 | 75.6 | 49 | 5 | 89.8 | ||
| Tumor size, mm | 0.059 | 0.117 | ||||||
| ≤20 | 28 | 1 | 94.4 | 19 | 0 | 100.0 | ||
| >20 | 72 | 19 | 73.6 | 77 | 9 | 88.3 | ||
| Histological differentiation | 0.449 | 0.862 | ||||||
| High/moderate | 55 | 13 | 76.4 | 60 | 5 | 91.7 | ||
| Poor | 33 | 6 | 81.8 | 33 | 3 | 90.9 | ||
| LVI | 0.354 | 0.314 | ||||||
| Absent | 46 | 8 | 82.6 | 49 | 3 | 93.9 | ||
| Present | 40 | 10 | 75.0 | 43 | 5 | 88.4 | ||
| PNI | <0.001 | 0.011 | ||||||
| Absent | 67 | 9 | 86.6 | 72 | 3 | 95.8 | ||
| Present | 13 | 7 | 46.2 | 14 | 3 | 78.6 | ||
| ER | 0.822 | 0.141 | ||||||
| Positive | 52 | 11 | 78.8 | 56 | 3 | 94.6 | ||
| Negative | 38 | 9 | 76.3 | 40 | 6 | 85.0 | ||
| PR | 0.017 | 0.035 | ||||||
| Positive | 38 | 4 | 89.5 | 41 | 1 | 97.6 | ||
| Negative | 52 | 16 | 69.2 | 55 | 8 | 85.5 | ||
| Hormone receptor | 0.822 | 0.141 | ||||||
| Positive | 52 | 11 | 78.8 | 56 | 3 | 94.6 | ||
| Negative | 38 | 9 | 76.3 | 40 | 6 | 85.0 | ||
| HER2 | 0.457 | 0.245 | ||||||
| Negative | 64 | 13 | 79.7 | 70 | 5 | 92.9 | ||
| Positive | 26 | 7 | 73.1 | 26 | 4 | 84.6 | ||
| Subtype | 0.813 | 0.110 | ||||||
| HR+HER2- | 42 | 9 | 78.6 | 46 | 2 | 95.7 | ||
| Others | 48 | 11 | 77.1 | 50 | 7 | 86.0 | ||
| VEGF | 0.745 | 0.076 | ||||||
| Low | 47 | 10 | 78.7 | 48 | 2 | 95.8 | ||
| High | 43 | 10 | 76.7 | 48 | 7 | 85.4 | ||
| Axillary nodal metastasis | 0.043 | 0.089 | ||||||
| No | 43 | 6 | 86.0 | 44 | 2 | 95.5 | ||
| Yes | 47 | 14 | 70.2 | 52 | 7 | 86.5 | ||
| Distant metastasis | 0.003 | |||||||
| No | 90 | 7 | 92.2 | |||||
| Yes | 6 | 2 | 66.7 | |||||
| Early-stage cancer | 0.090 | 0.009 | ||||||
| Yes | 67 | 12 | 82.1 | 67 | 3 | 95.5 | ||
| No | 23 | 8 | 65.2 | 29 | 6 | 79.3 | ||
Data for histological differentiation, lymphovascular and perineural invasion could not be pathologically confirmed for all the patients. VEGF, vascular endothelial growth factor; LVI, lymphovascular invasion; PNI, perineural invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR+HER2-, hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer.